How each medication works
Contrave and GLP-1 medications reduce appetite through entirely different mechanisms. Contrave combines two older drugs: naltrexone, an opioid-receptor antagonist, and bupropion, an aminoketone antidepressant (the same active ingredient as Wellbutrin). Together they act on brain pathways involved in appetite and food-related reward — the hypothalamus and the mesolimbic 'reward' system — to reduce hunger and food cravings. It is taken as an extended-release oral tablet, typically titrated up to two tablets twice a day (a total of 32 mg naltrexone / 360 mg bupropion), per the FDA label.
GLP-1 medications mimic gut hormones the body releases after eating. Semaglutide (the molecule in Wegovy and in the diabetes drug Ozempic) activates the GLP-1 receptor. Tirzepatide (Zepbound, and the diabetes drug Mounjaro) is a dual agonist that activates both GLP-1 and GIP receptors. These drugs slow stomach emptying and signal fullness to the brain, which reduces appetite and calorie intake. Wegovy and Zepbound are once-weekly self-injections given under the skin.
One honest clarification readers often need: Ozempic is FDA-approved to treat type 2 diabetes, not for weight loss. It contains the same molecule (semaglutide) as Wegovy, which is the version FDA-approved specifically for chronic weight management. Prescribing Ozempic purely for weight loss is off-label. When people compare 'Contrave vs Ozempic,' the on-label weight-loss comparison is really Contrave vs Wegovy or Zepbound.
Average weight loss: the trial numbers side by side
The clearest way to compare is the pivotal trials that supported each FDA approval. Contrave was studied in the COR (Contrave Obesity Research) program. In COR-I (Greenway et al., The Lancet, 2010; NCT00532779), adults on the full dose lost about 6.1% of body weight versus 1.3% on placebo over 56 weeks (intention-to-treat), and 48% of them lost at least 5% of their weight. In COR-II (Apovian et al., Obesity, 2013), the full dose produced about 6.4% loss versus 1.2% on placebo at 56 weeks, with 50.5% achieving at least 5% loss. People who completed treatment and stayed on the drug tended to lose more — roughly 8-9%.
The GLP-1 trials reported larger averages. In STEP-1 (Wilding et al., New England Journal of Medicine, 2021), semaglutide 2.4 mg (Wegovy) produced about 14.9% mean weight loss versus 2.4% on placebo over 68 weeks. In SURMOUNT-1 (Jastreboff et al., NEJM, 2022), tirzepatide (Zepbound) produced about 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg doses versus 3.1% on placebo over 72 weeks.
An important caveat: these were separate trials with different populations, durations, and designs, so the numbers are not a perfect head-to-head. But the gap is large and consistent, and it is why GLP-1s are generally considered the more powerful weight-loss option on average. That does not mean they are right for everyone — averages hide wide individual variation, and some people cannot take or tolerate a GLP-1.
Side effects and safety profiles
Both classes most commonly cause gastrointestinal side effects, and both are usually started at a low dose and titrated up to reduce them. For Contrave, the FDA label lists nausea as the most common adverse event (about 30% in trials), followed by constipation, headache, vomiting, dizziness, insomnia, and dry mouth. Contrave carries a boxed warning — the FDA's strongest — for suicidal thoughts and behaviors, because bupropion is in the antidepressant class; it can also raise blood pressure and heart rate and lower the seizure threshold.
For GLP-1s, the most common side effects are also GI: nausea, diarrhea, vomiting, and constipation, which tend to ease over time. Semaglutide and tirzepatide carry a boxed warning about thyroid C-cell tumors seen in rodent studies (a human risk that has not been established), and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both classes have been associated with rare but serious risks such as pancreatitis and gallbladder problems.
Neither medication is 'safer' in a blanket sense — the relevant risks depend entirely on your personal medical history, current medications, and mental-health history. This is one of the main reasons a licensed clinician, not a website, must make the call. Report any severe or persistent symptoms to your prescriber.
Who each may suit (this is general, not a recommendation)
Educationally, and without recommending anything for you specifically, here are the general trade-offs clinicians weigh. Contrave may appeal to people who strongly prefer a pill over an injection, who want a lower-cost option, or whose eating pattern is driven heavily by cravings and food reward (the mechanism it targets). It has also historically been considered when someone also has depression or is trying to quit smoking, because bupropion addresses those — though Contrave itself is not approved to treat those conditions.
GLP-1 medications are generally chosen when the priority is the largest average weight loss, when there is co-existing type 2 diabetes (the same molecules treat it), or when a once-weekly routine is preferred over twice-daily pills. Their downsides are higher cost, the need for injections, and supply and coverage variability.
Contrave is contraindicated for people with seizure disorders, uncontrolled hypertension, chronic opioid use, eating disorders (bulimia/anorexia), pregnancy, or recent MAOI use — so those factors alone can move a clinician toward a different option. The point is that neither drug is universally 'better'; the fit is individual, and a licensed clinician decides based on your full picture.
Cost and access
Cost is one of Contrave's clearest advantages. Without insurance, the retail price averages roughly $750 per month. But the manufacturer's programs bring it far lower: a cash price of $199 for 120 tablets, and as little as about $99 per month through its home-delivery (CurAccess) program, per Contrave's official savings pages (2024-2025). Insured patients may pay considerably less.
Brand GLP-1 injections list much higher — Wegovy and Zepbound have list prices in the four-figure range per month — though manufacturer cash-pay programs and self-pay vial options have brought real-world prices down substantially. Coverage varies widely by plan and often requires prior authorization. Because prices and programs change frequently, verify current numbers directly with the pharmacy, manufacturer, or a telehealth provider before deciding.
A note on compounded GLP-1s you may see advertised cheaply: compounded semaglutide or tirzepatide is not an FDA-approved finished drug, and its availability is limited and legally constrained. Treat those offers with extra caution and discuss them with a licensed clinician.
The bottom line and next step
GLP-1 medications produced meaningfully more weight loss than Contrave in clinical trials — roughly 15-21% for Wegovy and Zepbound versus about 5-6% for Contrave. If maximizing average weight loss is the goal, the data favor GLP-1s. But Contrave remains a legitimate, FDA-approved, needle-free, and much cheaper option that some people tolerate better or simply prefer, and certain health conditions make a GLP-1 the wrong choice.
There is no medication that is right for everyone, and nothing on this page is medical advice or a recommendation to start, stop, or switch anything. The correct next step is a conversation with a licensed clinician who can review your history and prescribe appropriately.
If you want to explore GLP-1 options, our comparison of licensed GLP-1 telehealth providers can connect you with a clinician who evaluates whether a GLP-1 is appropriate for you.